Medivation (NASDAQ: MDVN) is best known for developing therapies to treat serious diseases. Earlier in 2014 the biopharmaceutical company received FDA approval to expand …
(Marketwired) – 11/06/14 – Medivation, Inc. (NASDAQ:MDVN) today reported its financial results for the third quarter ended September 30, 2014.
2014 has been an eventful year on Wall Street. Now that the year is coming to an end, what stocks should investors be …
Maxim Group analyst Jason Kolbert maintained a Buy rating on Medivation (NASDAQ:MDVN) and slightly raised his price target to $118 (from $112), as …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff reaffirmed a Buy rating on Medivation (NASDAQ:MDVN) and increased his price …
In a research report published today, Wedbush analyst David Nierengarten reiterated an Outperfom rating on Medivation (NASDAQ:MDVN) with a $109 price target, ahead of the …
In a research report issued today, Canaccord analyst John Newman upgraded shares of Medivation (NASDAQ:MDVN) to Buy from Hold and doubled his price target to $132 …
In a research report pubished yesterday, Janney Capital analyst Kimberly Lee maintained a Buy rating on Medivation (NASDAQ:MDVN) with a $110 fair value, …
In a research report issued yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Medivation (NASDAQ:MDVN) with a price target of …
In a research report released August 8, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Medivation Inc. (MDVN) with a $110 …
